MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (” MyMD” or “the Company”), a professional stage pharmaceutical company devoted to expanding healthy life expectancy, today announced that the initial individual has been enlisted in the Firm’s Stage 2 medical test of lead prospect MYMD-1, an oral immune regulator medicine, as a therapy for delaying aging and expanding healthy life-span.
The primary endpoint for the Stage 2 double-blind, placebo-controlled medical test is to attain a decrease in the circulating degrees of (TNF-α), lump necrosis variable receptor I (TNFRI) and IL-6. TNF-α and also IL-6 are the proteins in the body that cause inflammation and also aid activate the procedure of aging. The additional actions of the trial will be the security, tolerability, and also pharmacokinetics in this population of people.
” In a Stage 1 professional trial of MYMD-1, we showed the medicine’s statistically significant effectiveness in lowering levels of TNF-α, a key player in causing pathological aging, in the blood. The FDA has authorized TNF-α decrease as the primary endpoint for our Phase 2 research, which we believe settings us well for an effective Phase 2 end result,” stated Chris Chapman, M.D., President, Director and Chief Medical Policeman of MyMD. “The initiation of person enrollment in this research breakthroughs our objective to slow the aging process, prevent loss of muscle cells in aging, limit frailty, and also extend healthy lifespan.”
MyMD has specified that there are no FDA-approved medicines for dealing with aging problems and also extending healthy lifespan people, a market expected to be a minimum of $600 billion by 20251 according to a significant financial investment financial institution. TNF-α blockers are one of the most prescribed drugs by revenue, a global market of roughly $40 billion annually,2 as well as, according to Nature Aging journal,3 a slowdown in aging that would raise life expectancy by one year is worth $38 trillion as well as by one decade deserves $367 trillion.
In addition to aging, MYMD-1’s distinct activity in regulating the body immune system and also treating chronic inflammation is being established for the therapy of autoimmune illness, consisting of rheumatoid joint inflammation (RA), multiple sclerosis (MS), diabetic issues, and inflammatory digestive tract illness.
” We mean to start creating methods for a Stage 2 pilot research of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman noted. “The increasing occurrence of rheumatoid arthritis and various other autoimmune and inflammatory conditions are driving need for TNF preventions like MYMD-1, and we believe our orally administered drug with very reduced poisoning would certainly be turbulent to the $60 billion market for RA if approved by the FDA for this indicator.”
Rheumatoid arthritis affects around 40 million individuals around the world.4.
Originally created for autoimmune conditions, MYMD-1’s primary function is to reduce the aging process, stop sarcopenia and frailty, as well as expand healthy life expectancy. Due to the fact that it can go across the blood-brain barrier as well as access to the central nerves (CNS), MYMD-1 is also positioned to be a feasible therapy for brain-related problems. Its system of action and also efficiency in diseases including numerous sclerosis (MS) as well as thyroiditis have actually been studied via collaborations with numerous academic establishments. MYMD-1 is also revealing assurance in pre-clinical researches as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-proliferation healing.
MYMD-1 has actually revealed performance in pre-clinical research studies in regulating the body immune system by carrying out as a careful inhibitor of lump death factor-alpha (TNF-α), a motorist of persistent inflammation. Unlike various other treatments, MYMD-1 has actually been shown in these pre-clinical research studies to precisely block TNF-α when it comes to be overactivated in autoimmune conditions as well as cytokine storms, but not block it from doing its typical task of being an initial -responder to any kind of routine kind of moderate infection. MYMD-1’s simplicity of dental application is an additional differentiator contrasted to presently available TNF-α blockers, all of which need delivery by injection or mixture. No authorized TNF prevention has ever been dosed orally. In addition, the medication is not immunosuppressive and also has actually not been shown to cause the severe negative effects typical with conventional therapies that deal with inflammation.
About MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a medical phase pharmaceutical business committed to prolonging healthy life-span, is concentrated on creating two unique restorative platforms that treat the root causes of condition instead of only resolving the signs and symptoms. MYMD-1 is a medicine system based on a professional stage little molecule that regulates the body immune system to manage TNF-α, which drives persistent inflammation, as well as other pro-inflammatory cell signaling cytokines. MYMD-1 is being established to delay aging, increase long life, as well as deal with autoimmune illness as well as COVID-19- linked anxiety. The Firm’s second medication system, Supera-CBD, is being developed to deal with chronic discomfort, addiction as well as epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and also is being established to resolve and improve upon the rapidly growing CBD market, that includes both FDA authorized drugs as well as CBD products not currently managed as medicines. For more details, see www.mymd.com.